| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 22 May 2024 | 14 May 2024 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - May 22, 2024 Allotment of Shares Grant of Stock Options under Strides ESOP Plan Recommendation of Final Dividend for FY ended March 31, 2024 Outcome of Board Meeting - May 22, 2024 - Change in Board composition and Management Outcome of Board Meeting - May 22, 2024 - Change in Management (As Per BSE Announcement Dated on 22.05.2024) | ||
| Board Meeting | 30 Jan 2024 | 22 Jan 2024 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday January 30 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2023 Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company effective February 1, 2024 (As Per BSE Announcement Dated on 30/01/2024) | ||
| Board Meeting | 2 Jan 2024 | 2 Jan 2024 |
| Investment in AMP Energy | ||
| Board Meeting | 30 Oct 2023 | 20 Oct 2023 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday October 30 2023 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. This is for your kind information and record purposes. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023. (As per BSE Announcement Dated on 30/10/2023) | ||
| Board Meeting | 25 Sep 2023 | 20 Sep 2023 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2023 inter alia to consider and approve We refer to Companys announcement of August 2 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of Indias top specialty pharmaceuticals CDMOs. We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday September 25 2023 to consider the above proposal. The Company will also host a call on Monday September 25 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal. Intimation of Scheme of Arrangement, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Scheme of Arrangement (As per BSE Announcement Dated on 25/09/2023) | ||
| Board Meeting | 7 Sep 2023 | 7 Sep 2023 |
| As part of internal restructuring within the group, Board of Directors of the Company at their meeting held on September 7, 2023 have approved acquisition of 100% shareholding in Strides Pharma Services Private Limited (SPSPL). SPSPL is currently a WOS of Arco Lab Private Limited, a WOS of the Company. Post the said acquisition, SPSPL shall be a WOS of the Company. Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular of July 13, 2023 relating to the proposed transaction is enclosed. | ||
| Board Meeting | 2 Aug 2023 | 25 Jul 2023 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023. Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 02/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
